阵发性夜间血红蛋白尿
伊库利珠单抗
医学
血红蛋白尿
溶血
贫血
重症监护医学
补体成分5
补体系统
免疫学
内科学
儿科
抗体
作者
Meryem Bektas,Catherine Copley-Merriman,Shahnaz Khan,Sujata P. Sarda,Jamile M. Shammo
出处
期刊:Journal of managed care & specialty pharmacy
[Academy of Managed Care Pharmacy]
日期:2020-12-01
卷期号:26 (12-b Suppl): S14-S20
被引量:11
标识
DOI:10.18553/jmcp.2020.26.12-b.s14
摘要
The current standard of care for paroxysmal nocturnal hemoglobinuria (PNH) are the C5 inhibitors eculizumab and ravulizumab, both monoclonal antibodies designed to target the complement protein C5, thereby preventing its cleavage and the formation of the terminal attack complex.C5 inhibitors have yielded substantial improvements in the treatment of PNH and changed the mortality and morbidity, as well as healthrelated quality of life of patients with the disease.These treatments target underlying intravascular hemolysis; however, they do not address extravascular hemolysis, resulting in incomplete response and remaining symptoms in some patients.Therefore, despite treatment with a C5 inhibitor, some patients still experience anemia with associated fatigue, transfusion needs, and impaired health-related quality of life.
科研通智能强力驱动
Strongly Powered by AbleSci AI